Industries
Neurodegenerative Disease Research
Neurodegenerative disease companies develop treatments for Alzheimer's, Parkinson's, ALS, and frontotemporal dementia, where academic research provides the majority of validated targets, biomarkers, and disease models. The field recruits neuroscientists from top medical schools and licenses iPSC neuron platforms, CRISPR screening results, and biomarker assays from university partners.
Details
- Companies
- BiogenEli Lilly NeuroscienceEisaiAC ImmuneProthenaDenali TherapeuticsNeurimmuneAlectorPassage BioPrevail Therapeutics
- Market Size
- $12B
- Target Researchers
- Neuroscientists, neuropathologists, and translational researchers specializing in protein aggregation, neuroinflammation, tau biology, alpha-synuclein, TDP-43, lysosomal pathways, and CNS drug delivery across Alzheimer's, Parkinson's, and ALS models
- Use Cases
- Aggregation inhibitor lead licensingNeuroinflammation target co-developmentBiomarker assay validation partnershipsCNS drug delivery platform accessPatient cohort and biobank accessiPSC neuron differentiation protocol transfer